Correspondence: Garry M Walsh Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom To serve our readership better, future editions of Therapeutics and Clinical Risk Management will once again feature the Editor’s comments and views on some of the articles published in that issue of ...

BACKGROUND In the absence of head-to-head trials, indirect comparisons of randomized placebo-controlled trials may provide a viable option to assess relative efficacy. The purpose was to estimate the relative efficacy of reduction of fractures in post-menopausal women, and to assess robustness of the results. METHODS A systematic literature review of multiple databases identified randomized p...

Osteonecrosis of the jaw (ONJ) is a serious adverse drug event that was initially reported with intravenous bisphosphonates (BPs) and more recently with other classes of drugs such as receptor activator of NF-κB ligand (RANKL) inhibitor, antiangiogenic agents, and mammalian target of rapamycin (m-TOR) inhibitors. The purpose of this study is to analyze the ONJ cases and the associated drugs in ...

BACKGROUND Analyses of phase III trials showed that denosumab was superior to zoledronic acid (ZA) in preventing skeletal-related events (SREs) irrespective of age, history of SREs, or baseline pain status. This analysis assessed the risk of SREs across additional baseline characteristics. PATIENTS AND METHODS Patients (N = 5543) from three phase III trials who had breast cancer, prostate can...

[This corrects the article on p. 491 in vol. 5, PMID: 26069790.].

The purpose of this study is to couple a cellular bone homeostasis model with the pharmacokinetics (PK) and mechanism of action of denosumab, an inhibitor of receptor activator of nuclear factor-kappaB ligand, to characterize the time course of serum N-telopeptide (NTX), a bone resorption biomarker, following single escalating doses in multiple myeloma (MM) patients. Mean PK and median serum NT...

Aim: To assess the calcium homeostasis after treatment with denosumab in women with non metastatic breast cancer Patients and Methods: We prospectively enrolled 42 female patients with osteoporosis, who were eligible for treatment with denosumab. Patients were divided in two groups. In Group A were included 24 healthy postmenopausal women (controls) and in group B were included 18 patients with...

OBJECTIVE Hypercalcaemia is an important cause of increased morbidity and mortality in patients with parathyroid carcinoma. Surgical resection is the mainstay of treatment but, equally, managing hypercalcaemia is of paramount importance. At present, few therapies have been shown to be effective in the most severe cases. This report describes the efficacy of denosumab in a patient with parathyro...

AA: alopecia areata RANK: receptor activator of nuclear factor kappa RANKL: receptor activator of nuclear factor kappa b ligand TNF: tumor necrosis factor INTRODUCTION In the last 2 decades, various biologic agents have been developed to treat autoimmune disorders. Along with their high clinical efficacy, these agents have been associated with several paradoxical proinflammatory or autoimmune r...